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SUMMARY
The transition of adolescents with refractory epilepsy to the care of adult neurologists
can be challenging. For those patients with epilepsy due to mitochondrial disorders,
Lafora disease, Unverricht-Lundborg disease, and GLUT1 deficiency syndrome, a suc-
cessful transition can be even more problematic for both caregivers and neurologists.
Many of these patients require dietary treatments (ketogenic and modified Atkins
diets) for long-term management of their epilepsy. For these patients, coordinating
transfer of their dietarymanagement is necessary.
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Children with epilepsy due to mitochondrial or metabolic
disorders can be among the most challenging faced by a
child neurologist in practice. Seizures can often be refrac-
tory and are typically only incompletely controlled by stan-
dard treatments, with periodic exacerbations in disease over
decades. Unlike several other epilepsy syndromes and con-
ditions, the likelihood of seizures being outgrown by adult-
hood is remote. Therefore, the issue of transition to adult
epilepsy care is very important to adolescents faced with
these conditions.
In this review, we discuss four important epilepsy condi-
tions that may prove challenging at times of transition.
These include mitochondrial disorders, GLUT1 deficiency
syndrome, Lafora body disease, and Unverricht-Lundborg
disease. Lastly, because the ketogenic diet (KD) can help
children with these disorders, recent evidence regarding
strategies to transition adolescents who are receiving dietary
therapy for epilepsy into adulthood are discussed.
Mitochondrial Disorders
Mitochondrial disorders can begin at any age, but the dis-
eases with onset during infancy or early childhood generally
have severe or fatal outcome in a few years. Therefore, tran-
sition of patients with these conditions may be more likely
in those with onset in later childhood. Epilepsy is frequent
during the evolution of mitochondrial disorders, with differ-
ent presentations in childhood and adulthood. These condi-
tions appear to cause selective neuronal damage, leading
to lesions that mimic ischemic damage, but lack evidence
of decreased tissue perfusion. Although these stroke-like
lesions may expand or regress dynamically, the critical
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factor that dictates prognosis is the presence of epilepsy.
Seizures may increase the energy requirements of the
already metabolically compromised neurons, establishing a
vicious cycle resulting in worsening energy failure and neu-
ronal death.
In pediatric patients, mitochondrial epilepsy is more fre-
quent due to mutations in nuclear DNA-located rather than
mitochondrial DNA (mtDNA)–located genes and vice versa
in adults. Differences between pediatric and adult
mitochondrial epilepsy concern the onset and frequency of
epilepsy, seizure type, type of electroclinical syndrome, and
the outcome.1,2 A series of 56 children with mitochondrial
disorders found that the outcome of epilepsy is often very
severe.3 Seizures were frequently preceded by failure to
thrive, psychomotor delay, ataxia, or multisystemic dys-
function in 47 patients (82.5%). Sixty percent of the patients
had several seizure types. Six age-related epilepsy pheno-
types could be identified: status epilepticus complicating
neonatal multivisceral deficiency (n = 2), neonatal myo-
clonic encephalopathy (n = 3), infantile spasms (n = 8),
refractory or recurrent status epilepticus (n = 21), epilepsia
partialis continua (n = 4), and myoclonic epilepsy (n = 18).
Except for infantile spasms, epilepsy was difficult to control
in most cases (95%). Valproate was administered to 25
patients, one of whom developed acute liver failure 6 days
later. Twenty-two patients (45%) died, half of them within
9 months from the onset of epilepsy.3 Adult patients most
frequently presented with generalized tonic–clonic seizures,
partial seizures, convulsive status epilepticus, or nonconvul-
sive status epilepticus. Adult mitochondrial epilepsy
appears to be less frequent than previously believed, but the
prevalence strongly depends on patient selection.1
Anticonvulsants recommended for mitochondrial epi-
lepsy include levetiracetam, lamotrigine, gabapentin, and
lacosamide. The outcome of mitochondrial epilepsy may be
more favorable if mitochondrion-toxic antiepileptic drugs
(AEDs; possibly valproate) are avoided.1
In a study of 78 patients, the most burdensome complaints
included fatigue, behavior and speech disturbances, epi-
lepsy, and muscle weakness. A high degree of limitations in
daily activities impacted quality of life and can greatly
impact the transition of patients into independent care
during adulthood. It is notable that there was a discrepancy
between what symptoms pediatricians estimated would be
most burdensome compared to the actual reports from care-
givers opinion.4 For patients who are transitioning to adult
care with these disorders, a close relationship between
geneticists, primary care providers with experience with
disabled adults, and neurologists is necessary. Anticonvul-
sant management is not different from other conditions, but
patients may also receive supplements and vitamins for
mitochondrial diseases that need to be monitored and pre-
scribed. Lastly, KD therapy may be helpful for mitochon-
drial disorders, so handling this aspect of transition is
critical and will be discussed later in this review.5
GLUT1 Transition
GLUT1 deficiency syndrome is a genetic condition associ-
ated with impaired glucose transport into the brain and an
abnormality in the gene SLC2A1.6 There are three main
phenotypes; (1) classical–acquired microcephaly, develop-
mental delay, and early onset seizures; (2) nonclassical–
developmental delay, complex movement disorders,
paroxysmal exercise–induced dyskinesia, and (3) minimal
symptoms/normal development, seizures (may be minor),
dyskinesia after prolonged fasting.7 Children with this condi-
tion do not outgrow it, so they need a plan for adult transition.
The literature on transition of GLUT1-deficient patients
into adulthood is minimal. Mental retardation is common;
therefore, planning for long-term care important. The treat-
ment of choice is the KD, which is not typically used beyond
several years in most patients with epilepsy. For children
with GLUT1 deficiency, however, they need to be aware of
the long-term side effects after many years, including kid-
ney stones, osteoporosis, bone fractures, and impaired
growth.8 In our experience, children in whom the KD is not
successful tend to have fewer issues with epilepsy and more
problems with abnormal movements.7
There are many unanswered questions regarding how to
manage dietary therapies long term for adolescents with
GLUT1-deficiency syndrome. Would less-restrictive diets
such as the modified Atkins diet (MAD) afford similar ben-
efits but fewer side effects?9 If utilized, would the MAD
provide enough ketones to improve not only seizures but
also cognitive dysfunction? Should adolescents with milder
forms of GLUT1-deficiency syndrome still receive dietary
therapy, or could it be safely weaned to discontinuation
before adulthood? Similarly as the genetic test for GLUT1
(SLC2A1) becomes more widely used and GLUT1-defi-
ciency syndrome is increasingly diagnosed, should adults or
family members of children with GLUT1 who test positive
be treated? At least currently we do not have the answers to
these questions. Research from several specialized, multi-
disciplinary centers worldwide that care for adolescents
with GLUT1-deficiency syndrome will be needed to answer
these questions.
Key Points
 Transition for mitochondrial disorders is more common
for those with less-severe, adolescent onset of epilepsy.
 GLUT1 deficiency syndrome is life long, but the ideal
ketogenic diet for young adults is uncertain.
Transition for patients with Unverricht-Lundborg syn-
drome is important as the epilepsy is milder and progno-
sis more variable than Lafora disease.
Ketogenic diet transition may be eased by switching to
the modified Atkins diet.
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Lafora and Unverricht-
Lundborg Diseases
Lafora disease was first described in 1921 and is due to
rare mutations in either EPM2A or EPM2B genes, coding
for laforin and malin, respectively.10 Onset is often in ado-
lescence and is associated with photosensitivity, negative
myoclonus, and early cognitive delay. Sadly, it is a progres-
sive condition with death typically within 6–12 years of
diagnosis. As adolescents with Lafora disease transition into
adulthood, it is important to provide rational pharmacother-
apy for seizures, recognizing the progressive nature and lack
of definitive treatment. Zonisamide may help control/
reduce seizure frequency and severity. Many adults will
have psychiatric comorbidities and require social guidance
and support from parent groups.
Unverricht-Lundborg disease tends to be more mild than
Lafora disease, but with similar myoclonic seizures and
photosensitivity that may lead to an initial misdiagnosis of
juvenile myoclonic epilepsy.11 This condition was first
reported in 1891 and is due to a mutation in the cystatin B
gene (21q22.3). Similarly to Lafora disease, Unverricht-
Lundborg disease presents first in early adolescence with a
milder, nonprogressive cognitive dysfunction but at times
more severe epilepsy. The epilepsy often stabilizes as does
the electroencephalography (EEG), andearly death is uncom-
mon. In one study of long-term outcomes, 20 patients were
followed for 26 years and in many the seizures resolved.12
The outcomes were extremely variable, ranging from normal
independence to highly restricted quality of life. Similar to
Lafora disease, the benefits of parent support groups and neu-
rologists familiarwith the disease are invaluable.
Ketogenic Diet Transition
For most patients receiving anticonvulsants, considering
(or having had) surgery, or vagus nerve stimulation, there
are few major issues when transitioning from a pediatric to
adult epileptologists. Minor issues may include less of a
need for dosing based on body weight, decreased require-
ment for liquid oral solutions, and relatively diminished use
of certain therapies (e.g., ethosuximide, adrenocorticotropic
hormone (ACTH), and hemispherectomy) in adulthood.
The transition of patients on KDs can be much more compli-
cated.
The ketogenic diet is a high fat, low carbohydrate dietary
therapy for patients with medication-refractory epilepsy.
Most patients receiving this treatment are children. To some
degree, this is due to the pediatric-specific etiologies it is
often used to treat such as myoclonic-astatic epilepsy, Dra-
vet syndrome, GLUT1 deficiency, infantile spasms, and
Lennox-Gastaut syndrome. In addition, adults are often per-
ceived as being too difficult to maintain on KDs due to their
inherent restrictiveness and time-intensive nature. As a
result, relatively few adult epileptologists and dietitians
have expertise or comfort in KDmanagement.
Overall, the need for this transition is often infrequent.
Most children remain on the KD for up to 2 years, at which
point it is weaned to discontinuation. Older adolescents
especially may be taken off the KD in preparation for transi-
tion to an adult provider. However, some children who have
the KD discontinued will have recurrence or worsening of
seizures with weaning of the KD, and require long-term
dietary management. What is the ideal way to keep these
children on their dietary therapy once they switch to an adult
neurologist?
We recently reviewed and published our experience at
Johns Hopkins Hospital transitioning patients on diets to
adult providers.13 Ten patients were identified over the past
20 years with current ages of 20–44 years. All started die-
tary therapy as children or adolescents (mean age
10.3 years, range 6–16 years), with all but one initially
starting with the classic KD. Patients in this study had pro-
longed use of dietary management (mean 15.5 years; range
4–32 years). Eight patients had moderate to severe develop-
mental delay and were dependent on parent or sibling care-
givers for food preparation.
Three major categories of transition options were identi-
fied as used by young adults with epilepsy on dietary therapy.
First, the most common (six patients), was a transition to the
Johns Hopkins Adult Epilepsy Diet Center (AEDC). The sec-
ond option (two patients) was to transfer care to an adult neu-
rologist who was not a member of a KD team. The third
option (two patients) was to continue care through a pediatric
KD center. Those patients followed in the AEDC were
slightly more likely to remain on dietary therapy following
transition (5 of 6 vs. 1 of 4, p = 0.12). The AEDC team was
motivated to help these patients, keep them on dietary ther-
apy, and provide adequate nutritional support. We believe an
adult epilepsy diet center is the ideal option, when present.
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